Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bringing Out the Usual – and Unusual – Cancer Genomics Suspects

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Several years ago, researchers sequencing lung cancer genomes encountered a number of red herrings.

After combing through thousands of genes in a large number of patients, they had come up with a list of likely genetic suspects tied to the disease. Most of these genes made sense – some had previously been implicated in cancer, others clearly played an important biological role. But the data also pointed to a group of genes encoding olfactory receptors – the proteins that allow us to smell. Why were so many of these genes cropping up? Could these possibly be culprit genes? In the end, researchers found that they were simply red herrings – distractions along the way to pinpointing the mutations driving cancer.

As cancer genomics scales up, more and more mutations can be detected. But in order for critical patterns and potential drug targets to emerge, researchers need to be able to eliminate the red herrings from their results and identify the genetic changes driving different cancer types. To do so, Broad researchers have surveyed the genetic landscape of cancer to better understand the spectrum of mutations within and across cancer types, and have used this information to develop a more sophisticated analytical methodology to detect key mutations. Known as MutSigCV, the new methodology is featured prominently in a paper appearing in Nature this week.

“Back in the days when there was very little data, researchers would get excited about seeing one mutation in a gene,” said co-first author Michael Lawrence, a Broad computational biologist. “But in this era of big data, thousands of samples are being sequenced and every gene has many mutations. We have to be able to support the idea that the mutation rate of a particular gene is above what we’d expect to see.”

Lawrence and his colleagues wanted to understand the source of the red herring problem. Most analytical approaches used for finding cancer genes take into account the overall genome-wide mutation frequency in a given type of cancer as well as a handful of other parameters. But these measures are often not enough to weed out unhelpful results. Mutations are not uniform across the genome, and some genes are ‘highly mutable,’ meaning that for a variety of reasons, they are more prone to accumulating mutations.

“Not taking these highly mutable genetic regions into account leads to declaring that genes in these regions have more mutations than expected and therefore likely were positively selected for during the cancer’s evolution,” said senior author Gad Getz, director of Cancer Genome Computational Analysis at the Broad. “Now we know that this could have been just by chance so there is really no evidence that these genes are actually involved in cancer.”

In order to factor in these highly mutable genes and other sources of problematic data, Getz’s team developed an algorithm that takes context into account. Any given nucleotide in the genome is influenced by three major kinds of context: its immediate, DNA neighbors (having an A, C, T, or G on either side); its location on a chromosome; and the type of cell it is in.

In the case of the olfactory receptor genes that kept turning up unexpectedly in the lung cancer data, a key clue would emerge when a visiting scientist named Paz Polak gave a talk to Getz’s lab. His talk had to do with the phenomenon of DNA replication timing. In order for a cell to divide and each daughter cell to receive a complete copy of the genome, all of the DNA must be duplicated. But this copying process does not happen all at once – some genes get copied early, and others are copied later (this animation shows the process over time). Genes that get copied later tend to be more prone to mutation. And olfactory receptor genes tend to get copied quite late.

“That was the real key to solving this mystery,” said Lawrence. “We went back to our data and looked at the olfactory receptors, and sure enough, they are uniformly late replicating.”

Using this criterion and many others, the researchers developed MutSigCV to account for context when ranking the most promising genetic findings. By looking at data from over 3,000 tumor samples representing 27 cancer types, the team was able to see the extraordinary range of mutation frequency and spectrum for tumors.

These maps show patterns that are unique to certain cancer types. For instance, skin cancer has a specific pattern or “signature” that reflects mutations induced by ultraviolet light; lung cancer’s signature is influenced by tobacco smoke; and other cancers – head and neck cancer, cervical cancer, and bladder cancer – all share a common signature likely tied to a response to infection.

Overall, the frequency of mutations varied by more than 1,000 fold between cancers with the lowest (pediatric cancers and leukemias) and the highest (melanoma and lung cancer) mutation rates.

With the ability to eliminate many suspicious genes, the researchers say it is now possible to start analyzing large cancer collections, including combined datasets from many cancer types. “We believe that this tool should be used in all studies — small or large — since the resulting gene list more accurately represents genes that have undergone positive selection in cancer,” said Getz. “Our goal is to use MutSigCV across cancer datasets to get the most comprehensive list of cancer genes.”

By combining MutSigCV with other MutSig tools, Getz’s team has already begun undertaking this challenge, looking across cancer types in what his group refers to as “pan-cancer” studies. Through this work, they hope to pinpoint genes that transcend cancer type and offer promising targets for drug treatment for many patients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Screen of Human Genome Reveals Set of Genes Essential for Cellular Viability
Using two complementary analytical approaches, scientists at Whitehead Institute and Broad Institute of MIT and Harvard have for the first time identified the universe of genes in the human genome essential for the survival and proliferation of human cell lines or cultured human cells.
Monday, October 19, 2015
GTEx: Useful Expression For Cancer Research
GTEx Project has recently published several papers reporting on findings from its two-year pilot phase.
Tuesday, May 26, 2015
In vivo CRISPR-Cas9 Screen Sheds Light On Cancer Metastasis And Tumor Evolution
Genome-scale study points to drivers of tumor evolution and metastasis, provides roadmap for future in vivo Cas9 screens.
Friday, March 06, 2015
Disorder in Gene-Control System is a Defining Characteristic of Cancer, Study Finds
Findings indicate that the disarray in the on-off mechanism is one of the defining characteristics of cancer.
Tuesday, December 23, 2014
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Thursday, November 27, 2014
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Friday, October 10, 2014
Study Expands the Cancer Genomics Universe
The universe of cancer mutations is much bigger than previously thought, and key cancer genes are still to be discovered.
Tuesday, January 28, 2014
Predicting Cancer’s Next Move
Research offers a new approach to studying drug resistance in cancer.
Monday, November 11, 2013
Study Finds Rules for Cancer Drivers
Any number of alterations to an individual’s genetic code has the potential to make a cell malfunction and proliferate into cancer tumors.
Monday, September 30, 2013
Broad Institute and Bayer Join Forces
The Broad Institute has entered into a strategic alliance with Bayer Healthcare in the area of oncogenomics and drug discovery.
Wednesday, September 11, 2013
Chemical Screen Points to New Line of Attack Against Neuroblastoma
In the war on neuroblastoma, the current chemical weaponry is reaching its limit.
Monday, June 10, 2013
ATARiS Informatics Platform Hits the Jackpot
ATARiS is one of several tools developed at the Broad Institute to precisely tune in to the signals within noisy datasets.
Wednesday, May 22, 2013
Researchers Unearth New Clues About How Prostate Cancer Evolved
With the help of a computational model, Broad researchers were able to reconstruct the genomes of prostate cancer cells.
Thursday, May 16, 2013
Endometrial Cancer Findings Emerge from Genome Sequencing Study
Novel tumor sub-types have been identified that could lead to better risk stratification and more individualized and targeted treatments.
Friday, May 10, 2013
Delivering on a Promise: Nanoparticles Carry siRNA to Tumours
RNA interference, a gene-silencing phenomenon discovered in the late 1990s, was hailed for its potential as a treatment in cancer and other diseases.
Friday, September 21, 2012
Scientific News
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Biomarkers That Could Help Give Cancer Patients Better Survival Estimates Discovered
UCLA research may also help scientists suppress dangerous genetic sequences.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!